ÉèΪÊ×Ò³ ¼ÓÈëÊÕ²Ø

TOP

Takepron intrauenous 30mg(Lansoprazole£¬À¼Ë÷À­ßò×¢Éä¼Á)
Ò©µê¹ú±ð£º  
²úµØ¹ú¼Ò£º ÈÕ±¾ 
´¦ ·½ Ò©£º ÊÇ 
ËùÊôÀà±ð£º 30ºÁ¿Ë/Æ¿ 10Æ¿/ºÐ 
°ü×°¹æ¸ñ£º 30ºÁ¿Ë/Æ¿ 10Æ¿/ºÐ 
¼Æ¼Ûµ¥Î»£º ºÐ 
Éú²ú³§¼ÒÖÐÎIJο¼ÒëÃû:
ÎäÌïÖÆÒ©
Éú²ú³§¼ÒÓ¢ÎÄÃû:
Takeda
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·1:
http://www.oneyao.net/article/2011/0811/article_26911.html
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·2:
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·3:
Ô­²úµØÓ¢ÎÄÉÌÆ·Ãû:
Takepron INTRAVENOUS£¨¥¿¥±¥×¥í¥ó¾²×¢Óã©30mg/VIAL 10VIAL/box
Ô­²úµØÓ¢ÎÄÒ©Æ·Ãû:
Lansoprazole
ÖÐÎIJο¼ÉÌÆ·ÒëÃû:
´ï¿ËÆÕ¡£¨¥¿¥±¥×¥í¥ó¾²×¢Óã©30ºÁ¿Ë/Æ¿ 10Æ¿/ºÐ
ÖÐÎIJο¼Ò©Æ·ÒëÃû:
À¼Ë÷À­ßò
ÔøÓÃÃû:
¼ò½é£º

 

²¿·ÝÖÐÎÄÀ¼Ë÷À­ßò´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£©
ÉÌÆ·Ãû£ºTakepron INTRAVENOUS 30mg
Ó¢ÎÄÃû£ºLansoprazole
ÖÐÎÄÃû£ºÀ¼Ë÷À­ßò×¢Éä¼Á
Éú²úÉÌ£ºÎäÌ﹫˾
ÖÎÁÆÀà±ðÃû³Æ
ÖÊ×Ó±ÃÒÖÖƼÁ
Åú×¼ÈÕÆÚ£º2006Äê12ÔÂ
É̘ËÃû
Takepron INTRAVENOUS 30mg.
»¯Ñ§˜‹Ôìʽ
Ò»°ãÃû
¥é¥ó¥½¥×¥é¥¾©`¥ë£¨Lansoprazole£©¡²JAN¡³
»¯Ñ§Ãû
(RS)-2-({£Û3-Methyl-4-£¨2,2,2-trifluoroethoxy£©pyridin-2-yl£Ýmethyl}sulfinyl)-1H-benzimidazole
·Ö×Óʽ
C16H14F3N3O2S
·Ö×ÓÁ¿
369.36
ÈÚµã
¼s166¡æ£¨·Ö½â£©
ÐÔ×´
À¼ËØplatourÊÇ°×É«~´øºÖ°×É«µÄ½á¾§ÐÔ·ÛÄ©¡£n, n -¶þ¼×»ù¼×õ£°·ÀïÈÝÒ×ÈÜ»¯£¬¼×´¼ÓÐÉÙÐíÈÝÒ×ÈÜ»¯£¬ËùÒÔ¼¸ºõ²»»áÈÜÓÚÒÒ´¼(99.5)¡£n¡¢n¶þ¼×±½±ûõ£°·ÈÜÒº(1→10)²»Õ¹Ê¾»ú¹âÐÔ¡£³ÐÈϽᾧ¶àÐΡ£
ҩЧҩÀí
1.×÷ÓûúÖÆ
±¾¼ÁÊÇθճĤ±Úϸ°ûµÄËáÉú³É²¿Î»¹ý¶Éºó,¾­¹ýËáÒýÆðµÄתÒÆ·´Ó¦»îÐÔ±»ÉíÌåºÍ½á¹¹×ª»»,¸ÃËáתÒÆÉú³ÉÎïËáÉú³É²¿Î»É«²Ê×÷ΪÖÊ×ӱõÄ×÷ÓÃ,h +-k +-atpaseµÄsh»ù½áºÏ,ÒÖÖÆø»îÐÔ,ÒÖÖÆËá·ÖÃÚ¡£
ѪҺÄý¹Ì¹¦Äܼ°ÑªÐ¡°åÄý¾Û¹¦ÄÜÔÚËáÐÔÌõ¼þϱ»Ç¿ÁÒÕÏ°­,¸ü×÷ΪѪҺÄý¹ÌµÄ½á¹ûÐγÉÁË¥Õ¥£¥Ö¥ê¥óÔÚËáÐÔÌõ¼þÏÂÒòθµ°°×øÈܽⱻ±¨¸æ,±»±¾¼ÁʹθÄÚphÉÏÉýʹѪҺÄý¹Ì¹¦Äܼ°ÑªÐ¡°åÄý¾Û¹¦ÄÜ,ÒÖÖÆθµ°°×ø»îÐÔ,¸ÄÉƳöѪ±íÏÖ³öÒÖÖÆ×÷Óá£
θËðÉËճĤµÄÐÞ¸´ÔÚËáÐÔÌõ¼þϱ»ÒÖÖÆ£¬²»¹ý±¾Ò©¼Á¿ÉÒÔͨ¹ýÒÖÖÆËáµÄ·ÖÃÚÀ´Ìá¸ßθÄÚph£¬´Ó¶ø´Ù½øËðÉËճĤµÄÐÞ¸´¡£
2.θ³öѪÒÖÖÆ×÷ÓÃ
ÔÚС°×Êó(¾²ÂöÄÚ×¢Éä)ÖУ¬¶ÔÒòÍÑѪÐÝ¿ËÒýÆðµÄθ³öѪ¾ßÓÐÒÖÖÆ×÷Óá£
3.θճĤËðÉËÒÖÖÆ×÷ÓÃ
¸ÃС°×Êó(¾²ÂöÄÚ×¢Éä)¿ÉÒÖÖÆÒò°¢Ë¾Æ¥ÁÖ»òÓ¡¶ÈÒ©ÖеÄθճĤËðÉ˵ÄÐγɡ£
4.θËá·ÖÃÚÒÖÖÆ×÷ÓÃ(24СʱθÄÚphÖµ¼à²â)
ͨ¹ý¶Ô½¡¿µ³ÉÈ˵ÄÒ»´Î30Ã×g1Ìì2´Î¾²ÂöÄÚ×¢É䣬¿ÉÈ϶¨³ÖÐøµÄθËá·ÖÃÚ×÷Óá£ÁíÍ⣬ÔÚ¾²Âö×¢Éä(Ô¼3·ÖÖÓ)»òµãµÎ¾²×¢(30·ÖÖÓ)ÖУ¬24СʱθÄÚph4 holdingʱ¼ä(ph4 holdingʱ¼äµÄ±ÈÀý)ÊÇÏàͬµÄ¡£ÔÙÕß,±¾Ò©µÄ´úлÐͱ»Åж¨µÄ½¡¿µ³ÉÈË1´Î30 mg1ÈÕ2´Î¾²ÂöÄÚ×¢ÉäµÄËá·ÖÃÚÒÖÖÆЧ¹û(ÿ24СʱµÄph4¥Û©`¥ë¥Ç¥£¥ó¥°¥¿¥¤¥à),ÔÚµÚÒ»Ììem(56 ~ 69%)¡¢pm(90%),5ÌìÔÚem(80 ~ 88%),pm(98%)¡£
ÊÊÓ¦Ö¢
²»ÄÜ¿Ú·þÏÂÃæµÄ¼²²¡
θÀ£Ññ¡£Ê®¶þÖ¸³¦À£Ññ£¬¼±ÐÔѹÁ¦Î¸À£Ññ£¬¼±ÐÔθճĤ²¡±ä
Ó÷¨ÓëÓÃÁ¿
ͨ³££¬³ÉÈË£¬Ò»´Î30mg½«Ò»´Î30mg»ìºÏÔÚÈÕ¾ÖÉúÀíʳÑÎÒº»òÈÕ¾Ö5%ÆÏÌÑÌÇ×¢ÉäÒº£¬Ò»Ìì2´Î¾²×¢£¬»òÕßÔÚÈÕ¾ÖÉúÀíʳÑÎÒº»òÈÕ¾Ö5%µÄÆÏÌÑÌÇ×¢ÉäÒº20mL£¬Ò»Ìì2´Î·ÅËɾ²Âö×¢Éä¡£
°ü×°
30mg
10Æ¿
ÖÆÔìÉÌ
ÎäÌïÒ©Æ·¹¤Òµ
×¢£ºÒÔÉÏÖÐÎÄ´¦·½×ÊÁϲ»¹»ÍêÕû£¬Ê¹ÓÃÕßÒÔÔ­´¦·½Îª×¼¡£
ÍêÕû˵Ã÷¸½¼þ£ºhttp://www.info.pmda.go.jp/go/pack/2329404F1020_1_12/
Takeda announced on August 20 that Japan's Ministry of Health and Welfare approved lansoprazole oral preparation, Takepron Capsules 15/Takepron OD Tablets 15, to prevent the recurrence of NSAIDs-related gastric and duodenal ulcers.
Takepron, a proton pump inhibitor developed by Takepron, was marketed in Japan in 1992. Its indications are gastric ulcer, duodenal ulcer and reflux esophagitis.
NSAIDs are mainly prescribed for the treatment of pain and inflammation. Long-term use may cause gastric or duodenal ulcers, but discontinuation may worsen the quality of life of patients, especially those with rheumatoid arthritis and osteoarthritis.
Takepron can prevent ulcer recurrence in patients with a history of ulcer and need to take low-dose aspirin or other NSAIDs for a long time. It is the only product approved for this indication on the Japanese market ¡£ 

¡¾´ó ÖРС¡¿¡¾´òÓ¡¡¿ ¡¾·±Ìå¡¿¡¾Í¶¸å¡¿¡¾Êղء¿ ¡¾ÍƼö¡¿¡¾¾Ù±¨¡¿¡¾ÆÀÂÛ¡¿ ¡¾¹Ø±Õ¡¿ ¡¾·µ»Ø¶¥²¿¡¿
·ÖÏíµ½QQ¿Õ¼ä
·ÖÏíµ½: 
ÉÏһƪ£ºGaster D Tablets 100¡Á10mg£¨Fam.. ÏÂһƪ£ºAltat Capsule 100¡Á75mg(Roxatid..

Ïà¹ØÀ¸Ä¿

×îÐÂÎÄÕÂ

ͼƬÖ÷Ìâ

ÈÈÃÅÎÄÕÂ

ÍƼöÎÄÕÂ